利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.048 秒)

    Chimeric double-stranded nucleic acid
    4.
    发明授权
    Chimeric double-stranded nucleic acid 有权

    公开(公告)号：US11034955B2

    公开(公告)日：2021-06-15

    申请号：US16410803

    申请日：2019-05-13

    申请人： National University Corporation Tokyo Medical and Dental University ,  Osaka University

    发明人： Takanori Yokota ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

    IPC分类号： C12N15/113 ,  C12N15/11

    摘要： A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

    Chimeric double-stranded nucleic acid
    5.
    发明授权
    Chimeric double-stranded nucleic acid 有权

    公开(公告)号：US10337006B2

    公开(公告)日：2019-07-02

    申请号：US15725845

    申请日：2017-10-05

    申请人： National University Corporation Tokyo Medical and Dental University ,  Osaka University

    发明人： Takanori Yokota ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

    IPC分类号： A61K31/712 ,  A61K31/7125 ,  C12N15/113 ,  C12N15/11

    摘要： A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

    Double-stranded agents for delivering therapeutic oligonucleotides
    6.
    发明授权
    Double-stranded agents for delivering therapeutic oligonucleotides 有权

    公开(公告)号：US11028387B2

    公开(公告)日：2021-06-08

    申请号：US14892664

    申请日：2014-05-30

    申请人： National University Corporation Tokyo Medical and Dental University

    发明人： Takanori Yokota ,  Kazutaka Nishina ,  Kotaro Yoshioka ,  Hidehiro Mizusawa

    IPC分类号： C12N15/113

    摘要： Disclosed are double-stranded nucleic acid agents that can deliver a therapeutic oligonucleotide within a biological sample, and methods for using the same. In one embodiment, the double-stranded nucleic acid agent comprises a first strand comprising a first RNA region, and a second strand comprising a first DNA region, wherein said first RNA region and said first DNA region are hybridized as a RNA/DNA heteroduplex. Said first strand further comprises a nucleic acid therapeutic oligonucleotide region that is capable of being cleaved from at least one nucleotide in said first RNA region. Methods for using the double-stranded nucleic acid agents include methods for delivering the therapeutic oligonucleotide as a single strand by cleaving it from at least a portion of the first RNA region. The methods further include delivering the double-stranded nucleic acid agent and thus the therapeutic oligonucleotide to a target site within the body of a treatment subject.

    CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
    8.
    发明申请
    CHIMERIC DOUBLE-STRANDED NUCLEIC ACID 审中-公开

    公开(公告)号：US20190270996A1

    公开(公告)日：2019-09-05

    申请号：US16410803

    申请日：2019-05-13

    申请人： National University Corporation Tokyo Medical and Dental University ,  Osaka University

    发明人： TAKANORI YOKOTA ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

    IPC分类号： C12N15/113 ,  C12N15/11

    摘要： A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

    Chimeric double-stranded nucleic acid
    9.
    发明授权
    Chimeric double-stranded nucleic acid 有权

    公开(公告)号：US10329567B2

    公开(公告)日：2019-06-25

    申请号：US16021165

    申请日：2018-06-28

    申请人： National University Corporation Tokyo Medical and Dental University ,  Osaka University

    发明人： Takanori Yokota ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

    IPC分类号： C12N15/09 ,  C12N15/113 ,  C12N15/11

    摘要： A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.